



IFW
1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants of: Voorberg, et al.

Group Art Unit: 1644

Serial No.: 09/674,752

Examiner: Maher M. Haddad

Filed: December 29, 2000


Docket: 294-86 PCT/US/RCE II

For: METHOD FOR DIAGNOSIS AND
TREATMENT OF HAEMOPHILIA A
PATIENTS WITH AN INHIBITOR

Dated: January 23, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450 on January 23, 2007*


Signature: 

SUPPLEMENTAL RESPONSE TO OFFICE ACTION

In response to the Office Action dated July 3, 2006, Applicants filed an Amendment and an unexecuted 37 C.F.R. §1.132 Declaration on December 4, 2006. Applicants submit herewith the executed §1.132 Declaration for entry into the above-identified file. The previously filed unexecuted copy is identical with this executed copy.

It is respectfully submitted that the present application is in all respects in condition for allowance which action is earnestly solicited. If for any reason the application is not deemed in condition for allowance, the Examiner is respectfully requested to contact Applicants' attorney at the telephone number indicated below.

Respectfully submitted,



Susan A. Sipos
Registration No.: 43,128
Attorney for Applicants

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
232230_1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants of: Voorberg, et al.

Group Art Unit: 1644

Serial No.: 09/674,752

Examiner: Maher M. Haddad

Filed: December 29, 2000

Docket: 294-86 PCT/US/RCE II

For: METHOD FOR DIAGNOSIS AND
TREATMENT OF HAEMOPHILIA A
PATIENTS WITH AN INHIBITOR

Dated: December 4, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope addressed to Commissioner for
Patents, PO Box 1450, Alexandria, VA 22313-1450on 12-4-6 Signature **DECLARATION UNDER 37 C.F.R. § 1.132**

The undersigned, Dr. Johannes Jacobus Voorberg of Paardenakker 20, 1531SR
Wormer, the Netherlands, herewith declares as follows:

1. I am an expert in the field of blood coagulation as evidenced by my resume,
which is attached as Exhibit A. Additionally, I am one of the inventors of the above-
identified U.S. Patent application, filed on December 29, 2000.
2. The Bethesda assay is recommended by the International Society on
Thrombosis Haemostasis as a test for determining factor VIII inhibitors in plasma from
patients. The Bethesda assay is used worldwide for the identification of factor VIII inhibitors.
3. A positive result of the Bethesda assay indicates that the antibodies in question
will actually inhibit factor VIII and result in an increased bleeding risk. Therefore, the said
Bethesda assay is very important for determining the presence of inhibiting antibodies.

4. Attached as Exhibit B is an article by Alan Giles et al. (*Thromb. Haemost.* 1998; 79: 872-5) written by members of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. The Bethesda assay is characterized as follows:

Subsequently, the Bethesda assay has achieved international recognition and is now the most frequently used approach for this purpose around the world. (See page 872, 2nd col., line 19.)

5. The *in vitro* data obtained with the Bethesda assay do indeed correlate well with the *in vivo* data in haemophiliacs with inhibitors. When the result of the Bethesda assay is negative, the medical doctor will take that as evidence for the absence of inhibiting antibodies. The absence of inhibiting antibodies means higher efficacy and normal half-life of the factor VIII given to the patient.

6. Attached as Exhibit C is an article by Jean Gilles et al. (*Blood* 2004, 103(7):2617-2623), which describes a study using anti-idiotypic antibodies directed against a factor VIII inhibitor. Anti-idiotypic antibodies can neutralise the inhibiting effect of factor VIII inhibitors *in vitro* (using an assay based on the Bethesda assay). See Figure 1C. In a mouse model for haemophilia A, identical results are obtained. See Figure 4. Therefore, the *in vitro* data found with the Bethesda assay correlate well with *in vivo* data obtained in test animals.

7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true. Further that these statements were made with the knowledge that willfully false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code, and that such willfully false statements may jeopardize the validity of the application of any patent issued thereon.

Dated: 2 January, 2007

230054

Respectfully submitted,


Dr. Johannes Jacobus Voorberg

EXHIBIT B

Scientific and Standardization Committee Communication

A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Haemophilia A Population of Canada

Alan R. Giles^{1,2}, Bert Verbruggen³, Georges E. Rivard², Jerome Teitel², Irwin Walker²
and the Association of Hemophilia Centre Directors of Canada*

On behalf of Factor VIII/IX Subcommittee of Scientific and Standardization
Committee of International Society on Thrombosis and Haemostasis

From the ¹AHCDC Factor VIII Inhibitor Reference Laboratory Kingston General Hospital, Kingston, Ontario, Canada, ²the Association of Hemophilia Centre Directors of Canada (AHCDC), Toronto, ON, Canada; ³the Central Laboratory for Hematology of Academic Hospital St. Radboud, Nijmegen, The Netherlands

Summary

The Bethesda assay is widely used to monitor the development and progress of Factor VIII:C inhibitors. Factor VIII stability in the substrate plasma (normal pool) is compromised by pH shift and reduction in protein concentration. Preliminary study, by Verbruggen and colleagues (8), suggested a reduction in spuriously positive assay results may result from buffering the normal pool plasma substrate with imidazole to pH 7.4 and substituting Factor VIII deficient plasma for imidazole buffer in the control incubation mix. These laboratory findings have now been confirmed by the performance of both the standard and the modified Bethesda assays in parallel on 877 patient samples screened during the Factor VIII:C Inhibitor Surveillance Program instituted following the conversion of all Canadian haemophilia A patients to recombinant Factor VIII. Although this study does not address the question of the clinical significance of spurious positive assays, these laboratory findings do support the conclusions of Verbruggen and the modified assay has recently been endorsed by the Factor VIII/IX Subcommittee of the SSC.

Introduction

The development of homologous antibodies to Factor VIII:C (F VIII:C) in the treatment of patients with haemophilia A (Factor VIII deficiency) remains as one of the major challenges in the treatment of this condition (1). The actual incidence reported varies widely from as low as 2.4 (2) to as high as 52% (3). The explanation for this discrepancy is clearly multifactorial, reflecting amongst other things known changes in prevalence during the natural history of the disorder in any one individual (4) and the clearly heterogeneous nature of the group of inhibitors that compromise F VIII function and/or survival following its infusion into a deficient individual (5). The latter clearly has a major influence with regard to the choices of methodological approach, any one of which may be more or less appropriate for the detection of a particular class or type of inhibitor. Despite this, however, there is clear need to standardize the methods used wherever possible in order to minimize variations in procedure as contributing factors to discrepant observations. Recognition of this led to a consensus of North American haemophilia treaters to recommend the adoption of an assay where the methodological approach and the F VIII inhibitory units assigned were standardized (6). Subsequently, the Bethesda assay has achieved international recognition and is now the most frequently used approach for this purpose throughout the world. Nonetheless, as acknowledged by its original proponents, it is clearly a compromise approach given that no one assay can be expected to capture all clinically significant inhibitors to F VIII:C (6). Despite this reservation, however, the introduction of new therapies, such as recombinant F VIII (rF VIII) and the prospect of gene therapy in the not too distant future, emphasizes the need for a consensual approach to be adopted in evaluating these treatment strategies with regard to any potential risk for the development of inhibitors. In monitoring the introduction of rF VIII, the Bethesda assay has been used in most studies as the gold standard for this purpose (7). Verbruggen and co-workers, however, have presented theoretical and clinical data suggesting that the use of the original method may give rise to spuriously positive results due to its failure to accommodate shifts in pH

*Association of Hemophilia Clinic Directors of Canada (AHCDC): Gerry Grosse, Man-Chiu Poon, John Wu, Robert Card, Kaiser Ali, Sara Israel, Morel Rubinger, Jordan Horst, Kulwant Gill, Martin Lowwood, Patricia J. McCusker, Irwin Walker, Mohan Pal, Bernadette Garvey, Jerome Teitel, Victor Blanchette, Alan Giles, David Lillicrap, Mariana Silva, Jeanne Drouin, Koon-Hung Luke, Mason Bond, Michele David, Georges Rivard, Jean St-Louis, Marlene Lepine-Martin, Christine Demers, Francois Jobin, Marie-Francoise Scully, Sean Dolan, Sheldon Rubin, Dorothy Barnard, Sue Robinson, Elizabeth Ross, Lawrence Jardine

Correspondence to: Alan R. Giles, MD, FRCPC, Department of Pathology, Richardson Laboratories, Queen's University, Kingston, ON K7L 3N6, Canada - Telephone: (613) 545-6342; FAX Number: (613) 545-2907; E-mail: giles@cliff.path.queensu.ca

and protein concentration which lead to loss of F VIII:C activity unrelated to the presence of inhibitory activity (8).

Late in 1993, the Canadian Blood Agency agreed to fund the conversion of all Canadian haemophilia A patients from plasma derived to rF VIII. Consequent to this, the Association of Hemophilia Centre Directors of Canada developed a surveillance program to monitor F VIII inhibitor development before and after this took place. In recognition of the possible influence of methodological differences in the performance of F VIII inhibitor assays in laboratories associated with the 24 Canadian regional haemophilia programs, all directors agreed to send patient samples, obtained before and for two years after conversion to rF VIII, to a national reference centre established under the supervision of one of the authors (ARG). Initially and by consensus amongst all the directors, the standard Bethesda assay was adopted and used exclusively during the first year of surveillance. Subsequently, however, with the sponsorship of the F VIII Subcommittee of the Scientific & Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH), it was agreed that all samples received by the reference centre would be assayed in parallel by the standard and Nijmegen modified Bethesda assay in order to provide comparative data from a large group of haemophiliacs all receiving the same replacement therapy and with all plasma samples collected by a standardized protocol and analyzed by a single laboratory. This study was not intended to examine the clinical significance of these findings, although when considered in the light of the data of Verbruggen and co-workers (8), does suggest that the modifications described by them should be adopted in all future surveillance programs where the Bethesda assay is used.

Materials and Methods

Note: Detailed protocols on blood collection/plasma sample preparation and assay performance are available from the principal author (ARG) at the address/E-mail (preferred) given above.

Plasma Preparation

A standard protocol was followed by all participating clinics. Blood was drawn by a two syringe technique via 19 gauge butterfly needle. The first draw (5 ml) was discarded and the second (10 ml) used to fill a vacutainer (Becton & Dickinson, NJ, USA) containing sodium citrate 0.11 M (3.2%) - 9 vol. blood to 1 vol. anticoagulant. Platelet-poor plasma (PPP) was obtained by centrifugation either by a single spin at 2,500 G for 15 min at 4° C or a double spin at 2,000 G for 10 min followed by a re-spin of the separated plasma at 2,500 G for 15 min at 4° C. Plasma was removed and aliquoted in 1.0 ml vol. into capped plastic tubes. All specimens were frozen either by placing on dry ice or in a low temperature freezer (-60° C or lower) within 2 h of venipuncture. All specimens were shipped on dry ice to the reference centre for assay.

Normal pool plasma was prepared by an identical protocol following collection of blood from 20 normal (10 male/10 female) volunteers. Each individual PPP sample was screened (APTT/PT/TT) prior to pooling to provide a given lot of normal pool plasma. Lots were collected approximately every two months. After pooling, each lot was divided into two and one buffered by adding solid imidazole (Sigma, St. Louis, MO, USA) to a concentration of 0.1 M with adjustment to pH 7.4 by the slow addition of 1N HCl with constant stirring at 4° C. The individual lots of buffered and non-buffered normal pool plasma were then frozen in 1.0 ml aliquots and stored at -70° C until required.

Factor VIII:C Assay

F VIII:C assay was measured in a one stage APTT-based clotting assay (9) on a Coag-a-mate X2 (Organon Teknica Canada, ON, Canada). APTT reagent and immunodepleted F VIII deficient plasma was obtained from Biopool Canada (Biopool, Burlington, ON, Canada).

Bethesda Assay Protocol

One sample from each patient was assayed for evidence of F VIII inhibitory activity by both the standard or classical Bethesda assay (CB) as described by Kasper and co-workers (6) and the Nijmegen modified Bethesda (NB) as described by Verbruggen and co-workers (8). In each case, the assays were performed concurrently. In the CB 1 vol of patient plasma was incubated with 1 vol of unbuffered normal pool plasma for 2 h at 37° C in a waterbath. At the same time, 1 vol of unbuffered normal pool plasma was incubated with imidazole buffer (0.05 M, pH 7.3) as a control mixture. In the case of the NB, 1 vol of patient plasma was incubated with 1 vol of imidazole buffered (pH 7.4) normal pool plasma for 2 h at 37° C together with a control mixture of 1 vol of imidazole buffered normal pool plasma (pH 7.4) with 1 vol of immunodepleted F VIII deficient plasma. After the 2 h incubation, in stoppered tubes, each mixture was assayed for residual F VIII activity. The percentage residual activity of the test versus the control mixture was determined and plotted logarithmically against units of inhibitor activity on an arithmetic scale. One unit of Bethesda inhibitor activity was determined as previously described by Kasper and co-workers as that resulting in a 50% loss of F VIII activity after 2 h incubation at 37° C (6). Where the percent residual found was between 25-75% Bethesda units the result was determined using the standard curve as previously described (6). Where the loss of activity was >75%, the assay was repeated with appropriate dilution with F VIII deficient plasma and the result calculated to account for this.

Patients

All patients surveyed were registered with one of the 24 comprehensive regional haemophilia programs serving the total haemophilia population in Canada. The basis for the surveillance program, i.e. to provide early warning of increased incidence of F VIII:C inhibitors should this occur following the use of rF VIII (rF VIII), was explained to each patient and/or their guardian. The blood samples obtained were collected during regular six-monthly and annual reviews at the clinic which they attended. The investigations were part of the normal battery of tests performed at that time. The details of the program were reviewed by the ethics review board at each of the institutions involved. In the majority of cases it was decided that a signed, informed consent was not required due to the investigations being performed being part of normal management procedures. In the minority, the recommendation to obtain written, informed consent from each patient or their guardian was followed. All patients reviewed below were converted from plasma-derived F VIII to rF VIII (Kogenate - Bayer, West Haven, CT, USA) during the period of the survey. As the majority of the patients had undergone conversion prior to the initiation of this comparative study, only a minority of pre-conversion samples were available for comparative assay purposes.

Survey of Laboratory Protocols for F VIII Inhibitor Development

The majority of laboratories continued to perform F VIII inhibitor assays using their own in-house method and reagents. A detailed survey was performed to identify methodological differences both between and within the assay systems used. Particular emphasis was placed on the use of commercial (usually lyophilized), normal and F VIII-deficient plasma preparations in the assay. The normal practice of buffering plasmas prior to lyophilization was considered particularly relevant in view of the proposed influence that this procedure could have on subsequent F VIII inhibitor assay performance.

Statistical Analysis

Where appropriate, statistical analysis was performed by unpaired Student's *t*-test.

Results

Eight hundred and seventy-seven Canadian haemophilia A patients have been converted from plasma-derived to recombinant F VIII (rF VIII) since October 1993. Plasma samples from all these patients




Fig. 1 Methodological differences between the performance of the standard or classical Bethesda Assay (6) and the modified (Nijmegen) assay (8) are illustrated

Table 1 Bethesda assay positive (≥ 0.5 BU) samples

positive CB/negative NB	13
negative CB/positive NB	1
positive CB/positive NB	34
negative CB/negative NB	829

CB = classical Bethesda assay

NB = Nijmegen modified Bethesda assay

Table 2 Incidence of F VIII:C inhibitors in Canadian haemophilia population September 1995 - June 1996

	Negative (< 0.5 BU)	Positive (≥ 0.5 BU)	\bar{x} Titre \pm S.D.
CB	830 (95%)	47 (5%)	15.48 \pm 34.57 Range 0.5-165
NB	842 (96%)	35 (4%)	33.44 \pm 69.72 Range 0.5-275

CB = classical Bethesda assay

NB = Nijmegen modified Bethesda assay

Table 3 Total distribution of Bethesda assay results

Results (BU)	CB	NB
0	792	824
$> 0 < 0.5$	38	18
≥ 0.5	47	35

CB = classical Bethesda assay

NB = Nijmegen modified Bethesda assay

were obtained prior to conversion and assayed by the standard or classical Bethesda assay (CB). Of these, 626 patients have been followed for one year and 326 for two years. Prior to evaluating the results obtained, 19 laboratories, serving the 24 haemophilia programs and normally performing the Bethesda assay, were surveyed as to the cut-off used in Bethesda units (BU) that would be reported as compatible with the presence of an inhibitor to F VIII:C. The recommendations ranged from minimal (> 0) to > 1.9 BU. The majority ($N = 9$) reported values of 0.5 BU or greater. By consensus therefore, this value has been used in reporting the outcome of the surveillance program. Preliminary analysis suggests that there has been no increase in the incidence of inhibitor development one and two years following conversion to rF VIII (10). A full report will be prepared and submitted after all patients have been followed for at least two years.

Commencing in October 1995, all samples were assayed by CB and the Nijmegen modification (NB). Eight hundred and seventy-seven assays have been run in parallel, of which 233 were performed on samples obtained from individuals prior to conversion from plasma-derived to rF VIII with the balance performed on post-conversion samples. Using the consensual but arbitrary cut-off of 0.5 BU or greater, 47 samples demonstrated the presence of an inhibitor using the classical method compared with 35 using the Nijmegen modified procedure. The distribution of results are shown in Table 1. Only one specimen was negative by CB (0.4 BU) and positive by NB (0.5 BU). More frequently, the relationship was reversed with 13 specimens being judged positive by CB (Range: 0.5-0.8 BU) and negative by NB (Range: 0-0.2 BU). As measured by these criteria, the incidence of inhibitors in the rF VIII Canadian haemophilia population was 5% as assessed by CB and 4% by NB (Table 2). In those individuals judged to be positive for inhibitor presence, the mean inhibitor titre was 15.48 ± 34.57 (SD) BU with a range of 0.5-165 BU by the classical method. Using the Nijmegen modified procedure, the mean titre was 33.44 ± 69.72 (SD) with a range of 0.5-275 BU. The differences were not significant ($P < 0.05$ - unpaired Student's *t*-tests).

Although the cut-off adopted in the Canadian surveillance program is in line with that used in many other reported studies, it does not necessarily reflect universal practice. Table 3 provides the distribution of all the assay results obtained, including those in the "grey zone", from minimal detectable inhibitory activity (> 0 BU) to < 0.5 . The trend for the Nijmegen modification to reduce the number of positive assays was also observed even in the "grey zone". Thirty-one samples exhibited some inhibitory activity ($> 0 < 0.5$ BU) by CB but were completely negative by NB. In eleven specimens this relationship was reversed.

Survey of Bethesda Assay Protocols Used by Participating Canadian Haemophilia Centre Laboratories

Nineteen of the participating laboratories followed the classical Bethesda assay in broad detail but a number of methodological variables and differences in reporting practices were identified. Full details of this survey will be reported elsewhere but of particular relevance to this report was the finding that nine laboratories used commercial lyophilized normal pool plasma in their assay systems. Cross-checking with the manufacturers confirmed that all were buffered prior to lyophilization but in no case was imidazole used for this purpose.

Discussion

These data support the preliminary findings of Verbruggen and co-workers in support of their prediction based, on study of F VIII stabil-

ity under varying conditions of pH and protein concentration, that failure to control these parameters during the course of performing the Bethesda assay may lead to the reporting of spuriously positive results (8). Although the Canadian F VIII Inhibitor Surveillance Program had arbitrarily elected a cut-off of 0.5 BU or greater, the data suggest that the conclusion reached was independent of the value chosen. As would be expected on theoretical grounds, the modified method appeared to be mainly influential in reducing the number of low titre inhibitors reported with the classical method, where F VIII was not protected from shifts in pH and protein concentration. There was also a trend towards higher recorded titres with the modified method in samples demonstrating inhibitory activity in the upper range of the titres observed in this study. The latter did not reach statistical significance, however, when compared to the results obtained with the un-modified assay. The significance of the low titre "grey zone" ($>0-0.5$ BU) results with the modified assay can only be determined by carefully controlled F VIII recovery/survival study, treatment outcome observations and follow up study with both laboratory and clinical monitoring. The primary objective of this study was to perform a detailed parallel comparison of the two assays' performance. Consequently, these data cannot address these issues but such follow-up studies are clearly warranted.

The finding that a number of laboratories using commercially available lyophilized and therefore buffered normal pooled plasma have, albeit inadvertently, adopted one of the two recommended Nijmegen modifications is of interest. This may well explain why the impact of the recommendations made have been questioned by some laboratories' experience in evaluating the modified assay against the standard procedure. It is entirely possible that the benefits observed in this study may have been blunted by partial adoption of the recommendations made through the use of commercial plasmas. Although none of the preparations available commercially are buffered with imidazole, there is no reason to suspect that other buffering systems cannot be substituted. This should, however, be confirmed by further study.

The use, in the Nijmegen modification, of F VIII deficient plasma in place of imidazole buffer, both as the substitute for patient (test) plasma in the control mixture and as a diluent of the patient sample if the assay result falls outside the permissible range, deserves additional comment. The commercial F VIII deficient plasma used in these studies was immunodepleted. Use of chemically depleted F VIII deficient plasma could theoretically give spurious results due to the presence of F VIII which, although functionless, could still provide the antigenic sites for F VIII antibodies in the test plasma. This theoretical consideration has been confirmed by personal observation (BV) and more recently by a detailed Canadian multicentre comparative assay study (11). Thus, in general, chemically depleted F VIII deficient plasma should not be used as a diluent in any F VIII inhibitor assay procedure including those described here. The use of F VIII deficient plasma as a substitute for buffer solutions also has significant cost implications. Theoretically, the objective of maintaining protein concentrations in the control mixture and following test sample dilution could be achieved using an albumin solution or other protein substitutes as a cheaper alternative. This possibility is currently under evaluation.

It should be emphasized that in proposing this approach to the laboratory monitoring of F VIII inhibitor development, Kasper and co-workers clearly recognized its limitations but recommended it as a standardized and manageable compromise for the monitoring of the majority of haemophilia A patients and comparing the results obtained from one laboratory to the next (6). The recommendations of the Nijmegen group are in line with this approach of standardizing and optimizing the assay procedure in order to facilitate inter-laboratory comparisons that are

essential for both monitoring the safety of F VIII replacement therapy with regard to inhibitor development and also in evaluating the efficacy of procedures designed to ablate or moderate established F VIII:C inhibitors in congenital or acquired F VIII:C deficiency. Thus, based on the findings reported, the recommendation that the standard or classical Bethesda assay should be modified to include buffering of the substrate normal pool plasma and the use of F VIII deficient plasma in place of imidazole buffer in the control mixture, as described under Methods, was recommended to the Subcommittee on F VIII and F IX of the Scientific & Standardization Committee of the International Society of Thrombosis and Haemostasis at their meetings in Barcelona and Dublin in June, 1996. This was accepted by consensus for recommendation to the membership and other interested parties.

Acknowledgments

The substantial contribution to the technical and administrative performance of these studies by Mae Louias Dwyre, Cindy Johnston, Kathy Blazer and Caroline Hensman is gratefully acknowledged, as is the contribution of Ms Barbara Saunders in the preparation of the manuscript. The willing participation of all our haemophilia A patients and the co-operation of the members of the Association of Hemophilia Centre Directors of Canada and the Hemophilia Program Nurse Co-ordinators in collecting the plasma samples was essential for the success of the program. Financial support was provided in part by the Canadian Blood Agency, Bayer Canada, Biopool Canada, Immunov Canada and Organon Teknika Canada. ARG is a Distinguished Research Professor of the Heart & Stroke Foundation of Ontario.

References

1. Kasper CK. Complications of Hemophilia A Treatment: Factor VIII Inhibitors. *Ann NY Acad Sci* 1991; 614: 97-105.
2. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The Natural History of Factor VIII:C Inhibitors in Patients With Hemophilia A: A National Cooperative Study. II. Observations on the initial Development of Factor VIII:C Inhibitors. *Blood* 1988; 71: 344-8.
3. Eurenforth S, Kreuz W, Scharrer I, Lindo R, Funk M, Gungor T, Kreckhardt B, Kornhuber B. Incidence of Development of Factor VIII and Factor IX Inhibitors in Haemophiliacs. *Lancet* 1992; 339: 594-8.
4. Rizza CR, Mathews JM. Effect of Frequent Factor VIII Replacement on the Level of Factor VIII Antibodies in Haemophiliacs. *Brit J Haematol* 1982; 52: 13-24.
5. Coombs MC, Glueck HL. The Persistence and Heterogeneity of Factor VIII:C Inhibitors as Demonstrated by Preparative Isofocusing. *Am J Hematol* 1990; 35: 73-9.
6. Kasper CK, Aledort LM, Counts RB, Edson JR, Frattoloni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JC, Shapiro SS, Shulman NR, Van Eys J. A More Uniform Measurement of Factor VIII Inhibitors. *Thromb Diath Haemorrh* 1975; 34: 869-72.
7. Lusher JM, Arkin S, Ahlidaard CF, Schwartz RS. Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A. *New Engl J Med* 1993; 328: 453-9.
8. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability. *Thromb Haemost* 1995; 73: 247-51.
9. Proctor RR, Rapaport SL. The Partial Thromboplastin Time with Kaolin: a Simple Screening Test for first-stage Plasma Clotting Factor Deficiencies. *Am J Clin Path* 1961; 36: 212-9.
10. Giles AR, Rivard GB, Teitel J, Walker I, and the Association of Hemophilia Centre Directors of Canada (AHCDC). The Prevalence of Factor VIII Inhibitor Development in the Canadian hemophilia Population Following the Wide-scale Introduction of High Purity Factor VIII Replacement Therapy. *Haemophilia* 1996; 2 Suppl 1: 89 (Abstract).
11. Giles AR, Rivard GB, Teitel J, Walker I, and the Association of Hemophilia Centre Directors of Canada (AHCDC). A Multicenter Study Comparing Assay Performance of "In House" Methods of Measuring F.VIII Inhibitors Versus Standardized Methodology (Manuscript in Preparation).

EXHIBIT C

In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody

Jean Guy G. Gilles, Sabrina C. Grailly, Marc De Maeyer, Marc G. Jacquemin, Luc P. VanderElst, and Jean-Marie R. Saint-Remy

Factor VIII (FVIII) administration elicits specific inhibitory antibodies (Abs) in about 25% of patients with hemophilia A. The majority of such Abs reacts with FVIII C2 domain. mAbBO2C11 is a high-affinity human monoclonal antibody (mAb) directed toward the C2 domain, which is representative of a major class of human FVIII inhibitors. Anti-idiotypic Abs were raised to mAbBO2C11 to establish their neutralizing potential toward inhibitors. One mouse anti-idiotypic mAb, mAb14C12, specifically prevented mAbBO2C11 binding to FVIII C2 domain and fully neutralized

mAbBO2C11 functional inhibitory properties. Modeling of the 3-D conformation of mAb14C12 VH and alignment with the 3-D structure of the C2 domain showed putative 31 surface-exposed amino acid residues either identical or homologous to the C2 domain. These included one C2 phospholipid-binding site, Leu2251-Leu2252, but not Met2199-Phe2200. Forty putative contact residues with mAbBO2C11 were identified. mAb14C12 dose-dependently neutralized mAbBO2C11 inhibitory activity in mice with hemophilia A reconstituted with human recombinant FVIII (rFVIII), allowing full expres-

sion of FVIII activity. It also neutralized in an immunoprecipitation assay approximately 50% of polyclonal anti-C2 Abs obtained from 3 of 6 unrelated patients. mAb14C12 is the first example of an anti-idiotypic Ab that fully restores FVIII activity in vivo in the presence of an anti-C2 inhibitor. The present results establish the *in vitro* and *in vivo* proof of concept for idiotype-mediated neutralization of a major class of FVIII inhibitors. (Blood. 2004;103:2617-2623)

© 2004 by The American Society of Hematology

Introduction

Hemophilia A is characterized by a functional deficiency of coagulation Factor VIII (FVIII), a cofactor for the formation of the intrinsic tenase complex, which is required for thrombin generation. Patients with hemophilia A suffer from spontaneous or posttraumatic bleeding into joints, muscles, or soft tissues. Replacement therapy using either plasma-derived or recombinant FVIII is complicated in about 25% of the patients by the development of specific antibodies (Abs) that neutralize FVIII function, also called inhibitors.^{1,2} The presence of an FVIII inhibitor precludes further specific replacement, thereby threatening the patient's life. To date, patients with FVIII inhibitor are treated by administration of bypassing agents, including recombinant FVIIa.³ Administration of high doses of FVIII over extended periods of time is considered in some cases, but such a therapy is extremely costly and limited to patients with recent and low inhibitor titers.⁴ Neutralizing anti-FVIII inhibitors nevertheless remains a major challenge and alternative; more specific strategies are warranted.

One of such strategies would be to directly neutralize the function of inhibitor Abs. Methods to inhibit the binding of inhibitory Abs to FVIII have been proposed, in which FVIII-derived peptides compete for the binding to inhibitor,⁵ but they have been limited practically by the absence of precise molecular information on such Abs and the risk of interfering with normal FVIII activity.

Despite its high molecular weight, FVIII presents only a limited number of B-cell epitopes, which are directly or indirectly involved in the function of the molecule.⁶ The majority of Abs react toward

the C2 domain of FVIII, which mediates interactions with von Willebrand factor (VWF) and phospholipids (PLs). We recently derived a human monoclonal antibody (mAb), mAbBO2C11, from the peripheral memory B-cell repertoire of a patient with severe hemophilia A and a FVIII inhibitor,⁷ and we demonstrated that mAbBO2C11 reacts with high affinity to the C2 domain of FVIII. Furthermore, the crystal structure of a complex of C2 and mAbBO2C11 Fab fragment demonstrated that the antibody recognizes a large conformational C2 epitope.⁸ Thus, mAbBO2C11 belongs to a prominent class of FVIII-specific Abs that inhibit the binding of FVIII to VWF and PL. Neutralizing anti-FVIII inhibitors nevertheless remains a major challenge. Alternative, more specific strategies are warranted.

Such neutralization could be achieved by using specific anti-idiotypic Abs. An Ab idiotype refers to the ensemble of determinants that are located within its variable part. Anti-idiotypic Abs are second-generation Abs directed toward the variable part of pathogenic Abs and, as such, are highly specific. On the basis of previous findings that anti-idiotypic Abs may neutralize FVIII inhibitor Abs in the plasma of healthy individuals^{9,10} and of patients with hemophilia A under tolerance induction by administration of high doses of FVIII,¹¹ it was predicted that idiotype regulation could be used therapeutically to interfere with the function of FVIII inhibitors.¹²

Recent evidence has indicated that only a proportion of anti-FVIII Abs exert an inhibitory activity¹³ and that FVIII inhibitors could emerge from only a limited number of B-cell precursors, at least with regard to light chain-specific Abs.¹⁴ Taken

From the Center for Molecular and Vascular Biology, University of Leuven, Belgium; and Laboratorium Biomoleculaire Modellering, University of Leuven, Belgium.

Submitted July 3, 2003; accepted November 17, 2003. Prepublished online as Blood First Edition Paper, December 11, 2003; DOI 10.1182/blood-2003-07-2207.

An inside Blood analysis of this article appears in the front of this issue.

Reprints: Jean Guy G. Gilles, Center for Molecular and Vascular Biology, Campus Geelhuysenberg, University of Leuven, Herestraat 49, B-3000 Leuven, Belgium; e-mail: jeanguyg.gilles@med.kuleuven.ac.be.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2004 by The American Society of Hematology

together, this information suggests that a limited number of anti-idiotypic Abs could be all that is required to control FVIII inhibitors.

Starting from mAbBO2C11, we have generated mouse anti-idiotypic Abs, and we provide in the present paper the *in vitro* and *in vivo* proof of concept, establishing the basis for idio-type-mediated neutralization of a major class of FVIII inhibitors.

Materials and methods

Reagents

Full-length human recombinant FVIII (rFVIII) was obtained as material for laboratory use only (rFVIII; Boyer, Berkeley, CA). Plasma-derived VWF was obtained from the Département Central de Fractionnement (DCF; Brussels, Belgium) and further purified as described.¹⁵ mAbBO2C11 IgG4 specific for the FVIII C2 domain has been fully described.¹⁴ Human mAbLE2E9 specific for the C1 domain¹⁵ and mouse mAbs directed toward different human FVIII domains or VWF were produced in our center (Center for Molecular and Vascular Biology [CMVB]).

Animals

CS7BL/6 FVIII^{-/-} with a target deletion in exon 16, initially obtained from Dr S. Antonarakis (Geneva, Switzerland), and BALB/c mice were bred in our animal facilities. All animal experiments were conducted according to the Ethical Committee Rules for Animal Experiments of the University.

Anti-idiotypic mAb production and characterization

mAbBO2C11 (10 µg) emulsified in complete Freund adjuvant (CFA) were injected subcutaneously in BALB/c mice, followed by 2 boost injections in incomplete Freund adjuvant (IFA) made at 2-week intervals. Antibody titers were measured by direct binding to mAbBO2C11-coated microtiteration plates. Clones were obtained after fusing splenocytes with the SP2 myeloma cells and expanded under limiting dilution. mAb14C12 Fab fragments were prepared by digestion with papain agarose beads (Pierce, Rockford, IL) and purified by passage over a protein-A Sepharose column. Real-time kinetic interaction between mAb14C12 and mAbBO2C11 was evaluated by surface plasmon resonance by using a Pharmacia Biosensor BLAcore instrument (Pharmacia Biosensor AB, Uppsala, Sweden). Purified mAbBO2C11 (5 µg/mL in 10 mM sodium acetate buffer, pH 5.0) was immobilized on the activated surface of a CM5 sensor chip. mAb14C12 was infused at various concentrations over the mAbBO2C11-immobilized sensor chip surface. Association and dissociation rate constants were determined as reported.⁷ For sequencing, mRNA from the mAb14C12 hybridoma was isolated by using the Quick Prep Micro mRNA Purification Kit (Amersham Pharmacia Biotech, Uppsala, Sweden). cDNA was synthesized with First-strand cDNA Synthesis Kit (Amersham Pharmacia Biotech). The cDNA encoding the heavy (VH) and light chain (VL) variable regions were amplified by polymerase chain reaction (PCR) using specific primers. PCR products were isolated from 1.5% agarose gel using the QIA quick Gel Extraction Kit (Qiagen, Hilden, Germany) and cloned using the pGEM-T Easy Vector system (Promega, Madison, WI). Plasmid DNA from positive colonies was isolated by using the High Pure Plasmid Isolation Kit (Roche Diagnostics, Mannheim, Germany) and sequenced in both directions with Sequencer (US Biochemical, Cleveland, OH).

Binding of mAb14C12 to mAbBO2C11 and its neutralization

Binding of mAb14C12 to mAbBO2C11. Microtiteration plates were coated with 2 µg/mL mAbBO2C11. Samples containing mAb14C12 were added to the plate, and bound mAb14C12 was detected by addition of a horseradish peroxidase (HRP)-labeled goat antimouse IgG (Bio-Rad, Hercules, CA). Optical density (OD) was evaluated at 490 nm in a microtiter plate reader Bmax (Molecular Devices, Sunnyvale, CA).

Inhibition of mAbBO2C11 binding to FVIII by mAb14C12. The concentration of mAbBO2C11 required to reach 80% of maximal binding to FVIII-coated plates was determined. This determination was carried out by using plates coated with 2 µg/mL rFVIII overnight at 4°C. All Ab

solutions were diluted in casein buffer (citrate buffer containing 0.5% casein, 9 g/L NaCl, pH 7.2). Bound mAbBO2C11 was detected by using an HRP-conjugated mAb specific for human Fc (Southern Biotechnology, Birmingham, AL). For inhibition assays, 60 µL of 2 µg/mL mAbBO2C11 was mixed with an equal volume containing various concentrations of mAb14C12. The mixture was preincubated for 1 hour at 21°C. Aliquots of 50 µL were applied in duplicates to FVIII-coated plates for a further incubation of 2 hours at 21°C. mAbBO2C11 binding was detected as earlier, and inhibition was calculated from the ratio of OD values.

Neutralization of mAbBO2C11 inhibitory activity in a functional FVIII assay. To evaluate the capacity of mAb14C12 or of its Fab fragment to restore FVIII function in the presence of the inhibitor mAbBO2C11, we first determined the concentration of mAbBO2C11 required to inhibit 80% of FVIII activity in a functional chromogenic assay (Dade Behring, Marburg, Germany) by using 1 IU/mL rFVIII. The same determination was made with a total immunoglobulin G (IgG) fraction and with affinity-purified polyclonal anti-FVIII Abs obtained from the mAbBO2C11 donor. The amount of mAbBO2C11 (or of polyclonal Abs) required to inhibit 80% of FVIII activity was mixed with an equal volume of various concentrations of mAb14C12 or of its Fab fragment. The mixtures were incubated for 1 hour at 37°C before addition of rFVIII. An aliquot of the mixture was retrieved after a further 1-hour incubation at 37°C and added to the chromogenic assay reagents. Control experiments included rFVIII incubated alone or with an Ab of unrelated specificity.

3-D modelling and alignment of mAb14C12 with the C2 domain

The 3-D model of the variable parts of mAb14C12 was established by submitting the corresponding amino acid sequences to the Web Antibody Modelling (WAM; University of Bath, Swindon, United Kingdom; <http://antibody.bath.ac.uk/>). This algorithm takes into account both conserved structures of framework regions corrected for variations in particular beta strands and the large sequence and structure variability of complementarity determining regions (CDRs), which fall into one of the canonical classes,¹⁶ as well as the particular sequence of the CDR3. The method combines database and conformational searches, energy screening, and structural-determining residue filtering. Alignment of C2 domain and variable parts of mAb14C12 was carried out by combining manual alignment of secondary structures with the use of the Kabach-Sander algorithm,¹⁷ and global sequence alignment was calculated with the Myers-Miller algorithm.¹⁸ The result was then refined by juxtaposing the 3-D structure of C2 domain¹⁹ and the WAM model of mAb14C12 Fv.

Inhibition of FVIII binding to VWF and PL

The capacity of mAb14C12 to interfere with the binding of FVIII to either VWF or PL was investigated as follows. Microtiteration plates were coated with an anti-VWF Ab followed by purified VWF as described.¹⁵ mAb14C12 (1.25 µg/mL in phosphate-buffered saline [PBS] containing 0.5% casein) was mixed with an equal volume of FVIII at a final concentration of 1 IU/mL. Fifty microliters of the mixture was then added to the VWF- or PL-coated plates, and the plates further were incubated for 2 hours at 21°C. The binding of the FVIII to VWF was detected by the addition of 2 µg/mL biotin-labeled mAb15 (an anti-heavy chain-specific antibody), followed by avidin-peroxidase and a specific substrate. To assess FVIII binding on PL, plates were coated with phosphatidyl serine diluted at 10 µg/mL in methanol, and the capacity of mAb14C12 to inhibit the binding of FVIII to PL was investigated by following the same procedure as for the VWF assay. Control experiments included the substitution of mAb14C12 by mAbBO2C11, known to inhibit the binding of FVIII to both VWF and PL.⁷

Binding of mAb14C12 to anti-FVIII antibodies of unrelated donors and mouse

Cloning of the FVIII C2 domain cDNA fragment and expression in a reticulocyte transcription/translation system. The DNA fragment encoding for the C2 domain was generated by PCR using primers bound by the restriction sites *HindIII* and *NatI*. Sense primer, named according to the first FVIII amino

acid residue encoded, was as follows: 2124, 5'-GATGCGAAGCTTGTCTTCTTGGCAATGTGQATTCA-3'. The antisense primer, named according to the last encoded amino acid residue, was as follows: 2332, 5'-TTCTCGACTTGGCGCCCGCTAGAGGTCCTGTGCCTCGCAGCC-3'.

The PCR product was subcloned in frame into Signal pglplus (R&D Systems Europe Abingdon, United Kingdom) and controlled by sequencing in both directions with the use of an ABI genetic Analyser 3.10 (Applied Biosystems, Foster City, CA).

A mixture containing all amino acids except methionine was added, together with 35 S-methionine (Amersham, Bucks, United Kingdom). The presence of C2 in the supernatant was checked by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) followed by autoradiography, showing a single band with the expected molecular mass of 21 kD.

Immunoprecipitation assay. The capacity of polyclonal anti-FVIII human Abs to recognize C2 was evaluated as described.⁷ The assay was adapted to determine whether mAb14C12 could prevent the binding to the C2 domain. Assays were carried out for plasma samples from 7 unrelated patients with hemophilia A inhibitor, including the patient from whom mAbBO2C11 was derived. Thus, mAb14C12 was diluted to final concentrations of 50, 150, or 450 μ g/mL in 500 μ L 50 mM Tris (tris(hydroxymethyl)aminomethane)-HCl buffer, pH 7.5, containing 150 mM NaCl, 0.1% Nonidet NP-40, 1 mM EDTA (ethylenediaminetetraacetic acid), 0.25% gelatin, and 5% bovine serum albumin (BSA; NET-gel buffer). Undiluted plasma (20 μ L) containing polyclonal anti-FVIII antibodies was added to each vial, and the mixtures were incubated for 1 hour at 4°C. From 1 to 3 μ L L-(35 S)methionine-labeled FVIII C2 domain was then added to the mixture for a further incubation of 1 hour at 4°C. Protein-A Sepharose (20 μ L; Amersham Pharmacia Biotech) was then added to each vial, and the suspensions were again incubated for 1 hour at 4°C. Sepharose beads were centrifuged and washed twice with NET-gel buffer. Bound antigen/antibody complexes were eluted from beads by boiling for 2 minutes in 30 μ L SDS gel-loading buffer. Supernatant (2 μ L) was taken and diluted in 20 μ L Lumasafe (Lumas LSC, Groningen, The Netherlands) for radioactivity counting.

As positive control, an aliquot of 2 μ L mAbBO2C11 (1 mg/mL in PBS) was added to each of the mAb14C12 solutions, and the experiment was carried out as described earlier for polyclonal antibodies.

Binding of mAb14C12 to anti-FVIII mouse mAbs. Microtiteration plates were coated with PBS containing 2 μ g/mL mouse mAb to various FVIII domains, including the C2 domain. Plates were washed and further incubated for 2 hours at room temperature with biotin-labeled mAb14C12, followed by washing and sequential addition of streptavidin peroxidase and its substrate. mAb14C12 binding was evaluated by OD reading described earlier.

In vivo assays

Effect of mAb14C12 on FVIII clearance. To ensure that mAb14C12 did not modify FVIII clearance, C57BL/6 FVIII^{-/-} mice were injected with 10 μ g/mL mAb14C12 or an IgG2a mAb of unrelated specificity, followed 15 minutes later by an intravenous injection of 1 IU rFVIII. Blood samples were collected by venipuncture after 180 and 360 minutes. Residual FVIII activity was evaluated by using a functional chromogenic assay (Dade Behring).

Neutralization of mAbBO2C11-mediated FVIII inhibition by mAb14C12. The assay was run essentially as described,²⁰ except for the use of mAb14C12 instead of peptides. Briefly, C57BL/6 FVIII^{-/-} mice

were reconstituted by intravenous injection of 1 IU rFVIII, which gives a concentration of 0.5 IU/mL and a reaction half time ($t_{1/2}$) of 180 minutes.²¹ Residual FVIII activity was measured ex vivo by using a functional chromogenic assay on blood obtained by cardiac puncture. Three mice were used under each experimental condition. Mice were injected intravenously with 100 μ L mAbBO2C11 at concentrations that ranged from 10 to 2.5 μ g/mL in PBS followed 30 minutes later by 1 IU rFVIII, and the concentration resulting in 90% inhibition of FVIII activity (ie, 0.5 μ g) was selected for neutralization assays. Controls included injection of a human IgG4 antibody of unrelated specificity. In a first series of experiments, complexes of mAbBO2C11 and mAb14C12 were formed prior to injection. Thus, 10, 1, or 0.1 μ g mAb14C12 was mixed with 0.5 μ g mAbBO2C11 in 100 μ L PBS for 30 minutes at 37°C before the injection, followed by 1 IU rFVIII. Control experiments included mice injected with saline, mAbBO2C11 alone, mAb14C12 alone, and mAbBO2C11 mixed with an IgG2a mAb of unrelated specificity. In a second series of experiments, the capacity of mAb14C12 to combine with, and neutralize, mAbBO2C11 in vivo was evaluated. Thus, groups of 3 FVIII^{-/-} mice were injected intravenously with 0.5 μ g mAbBO2C11 or saline. After 30 minutes, each mouse received a second 100 μ L intravenous injection of a mixture containing 1 IU rFVIII plus various amounts of mAb14C12, ranging from 0.1 to 10 μ g. Blood samples were collected as described earlier for assessing residual FVIII activity.

Results

Anti-idiotypic Ab, mAb14C12, neutralizes in vitro the FVIII inhibitory activity of human mAbBO2C11

BALB/c mice were immunized with mAbBO2C11, a human anti-FVIII inhibitor Ab that recognizes a major determinant of the C2 domain.⁷ The supernatants of 8 clones reacted with mAbBO2C11 but not with an unrelated IgG4 κ or with another human mAb specific for FVIII C1 domain. Two of these clones produced Abs that inhibited the binding of mAbBO2C11 to FVIII in a dose-dependent manner and neutralized the FVIII inhibitory activity of mAbBO2C11 in a functional assay. Figure 1 shows the results for one of the 2 mAbs, mAb14C12 (IgG2a). It can be seen that mAb14C12 specifically binds to mAbBO2C11, whereas it does not bind to a human anti-C1 mAb (Figure 1A). mAbBO2C11 binding to FVIII can be inhibited in a dose-dependent manner (Figure 1B). Fifty percent of the neutralization of the inhibitory activity was obtained in a chromogenic FVIII activity assay at a 1:2 mAbBO2C11/mAb14C12 molar ratio (Figure 1C). Fab fragments were prepared from mAb14C12 and shown to neutralize 50% of mAbBO2C11 inhibitory activity at a 1:8 mAbBO2C11/mAb14C12Fab molar ratio (Figure 1C), thereby confirming that the neutralization properties of mAb14C12 were brought about by residues located in the Ab variable parts.




Figure 1. Specificity and dose-dependent neutralization properties of mAb14C12. (A) mAb14C12 binds to microtiteration plates coated with mAbBO2C11 but not to a human IgG4 Ab of unrelated specificity or to an anti-FVIII C1 domain mAb (mAb14C12). (B) mAb14C12 inhibits the binding of mAbBO2C11 to plates coated with FVIII. In panels A and B each point represents the mean of 2 determinations \pm SD. (C) mAb14C12 or its Fab fragment neutralizes the FVIII inhibitory activity of mAbBO2C11 in a functional chromogenic assay as measured by single determination.

2620 GILLES et al

BLOOD, 1 APRIL 2004 • VOLUME 103, NUMBER 7




Figure 2. Homology between the C2 domain of FVIII and VH region of mAb14C12. (A) The sequence homology between the variable parts of mAb14C12 and the C2 domain of FVIII, including one PL binding site (Leu2251-Leu2252), is primarily carried by the VH region. (A) Views of a model structure of the FVIII C2 domain on which amino acids Leu2251 and Leu2252, highlighted in black, can be aligned with identical residues Leu102 and Leu103 of the VH mAb14C12. (B) Sequence alignment resulting from combination of data obtained by secondary structure alignment, global sequences alignment, and 3-D structural comparison are shown. Homologue residues between C2 domain and mAb14C12 are highlighted in black; similar residues are highlighted in gray. For mAb14C12, CDR position is indicated above the sequence.

The efficient neutralization of mAbBO2C11-mediated inhibitory activity prompted us to measure the binding affinity of mAb14C12 for mAbBO2C11. This measure was carried out by surface plasmon resonance, which showed association and dissociation rate constants of $5 \times 10^3 \text{ M}^{-1}\text{s}^{-1}$ and $5 \times 10^{-3} \text{ s}^{-1}$, respectively. Interestingly, these values are comparable to those calculated for the binding of mAbBO2C11 to FVIII,⁷ in keeping with the molar ratio of mAbBO2C11/mAb14C12 required to neutralize the inhibitory activity of mAbBO2C11 at equilibrium.

As mAbBO2C11 represents a significant part ($\pm 70\%$) of the total inhibitory activity present in the plasma of the patient from whom it had been derived,⁷ we checked whether the capacity of mAb14C12 to neutralize mAbBO2C11 inhibitory activity could also be observed when using the plasma, a total IgG fraction, or a polyclonal preparation of affinity-purified anti-FVIII Abs, all obtained from the patient from whom mAbBO2C11 was derived. Thus, the volume of plasma or amount of polyclonal IgG antibodies was determined, which inhibited by 80% the activity of 1 IU/mL FVIII, as described in "Neutralization of mAbBO2C11 inhibitory activity in a functional FVIII assay." To this plasma volume or amount of polyclonal IgG an aliquot of mAb14C12 was added containing different concentrations of this antibody. Incubation of the mixtures and assay of FVIII residual activity were carried out as described in "Materials and methods." A maximum of 60% neutralization of FVIII inhibition was obtained (data not shown), whereas full neutralization was observed with the positive control containing mAbBO2C11. This finding confirmed that mAbBO2C11 represented a major part of the repertoire of inhibitor antibodies in this patient and that efficient neutralization could be achieved directly in plasma.

mAb14C12 shows extended homology with the C2 domain

The sequence of mAb14C12 was aligned with that of the FVIII C2 domain. A significant homology was found between the C2 domain and the VH region. Figure 2 shows that 31 amino acid residues were found either identical or similar. This included 13 residues associated with CDR regions, but clustering to the CDR1 (6 residues) and CDR3 (6 residues). Interestingly, a significant contribution is observed from residues located in framework regions (18 amino acids). Moreover, only 2 residues (marked with an asterisk) of the VH region are mutated from the germ line sequence of mAb14C12. All 31 residues are surface exposed on C2, according to the crystal structure of the C2 domain¹⁹ (Figure 2), as well as on mAb14C12 VH region. A salient feature of this alignment is that it involves 1 of the 2 C2 PL binding sites made of Leu2251 and Leu2252 (total surface of 180 Å²), which correspond to Leu102 and Leu103 in mAb14C12 VH CDR3, whereas the second site (Met2199 and Phe2200) is not represented. Taken

together these observations indicate that the VH region of mAb14C12 in its germ line configuration carries an extended homology of the C2 domain.

mAb14C12 does not interfere with FVIII binding to either VWF or PL and does not reduce FVIII clearance rate from the circulation

The extended homology between the C2 domain and mAb14C12 VH, which involved FVIII VWF and PL binding sites, prompted us to verify whether mAb14C12 was able to inhibit the binding of FVIII C2 domain to VWF and/or to PL. No such inhibition was observed for either VWF or PL in the presence of mAb14C12, whereas control experiments carried out in the presence of mAbBO2C11 showed complete inhibition in both cases (Table 1). As mAb14C12 carries only one of the PL binding sites of C2 (made of Leu2251 and Leu2252), we also checked whether the antibody could interfere with the binding of a mutant of FVIII with a deletion of Ala2201, known to alter the PL-binding capacity through Met2199 and Phe2200.²³ No inhibition was found (data not shown), indicating that absence of inhibition of C2 binding to PL was not solely related to absence of the Met2199-Phe2200 residues.

The clearance of FVIII is at least in part due to the binding of the C2 domain to the lipoprotein-receptor-related protein (LRP) receptor,^{23,24} and could, therefore, be reduced by mAb14C12. This was examined in FVIII^{-/-} C57BL/6 mice reconstituted by tail injection of 1 IU human rFVIII. Previous calculation has shown that the average human FVIII $t_{1/2}$ in this model was 180 minutes.²¹ The

Table 1. Effect of mAb14C12 on FVIII binding to VWF and PL and clearance rate

	FVIII + mAb14C12	FVIII + mAbBO2C11
FVIII binding to VWF, %	100	ND
FVIII binding to PL, %	08	3
Residual FVIII activity, IU/mL	0.34	ND

ND indicates not determined.

The capacity of mAb14C12 to interfere with the binding of FVIII to VWF or PL was evaluated in enzyme-linked immunosorbent assay (ELISA). Microtiter plates were coated with VWF or PL as described in "Materials and methods." FVIII (1 IU/mL) was preincubated with buffer alone, or buffer containing 1.25 µg/mL of either mAb14C12 or mAbBO2C11 as a control, and the mixtures were added to VWF- or PL-coated plates. The residual binding of FVIII was evaluated by sequential addition of a biotin-labeled FVIII heavy chain-specific mAb (mAb15) and avidin-peroxidase. Assays were made in duplicate. Results are shown as percentages of residual FVIII binding, taking preincubation with buffer alone as 100%.

The effect of mAb14C12 on FVIII clearance was measured by injecting 1 IU FVIII intravenously in C57BL/6 FVIII^{-/-} mice, alone or 15 minutes after intravenous injection of a single dose of 10 µg mAb14C12. Bleeding was carried out at 180 minutes, namely the expected FVIII $t_{1/2}$ in this animal model,¹⁷ and the residual FVIII activity was measured in a chromogenic assay (described in "Materials and methods"). The 0.34 IU/mL measured in mice pretreated with mAb14C12 compares with the 0.32 IU/mL measured in mice injected with FVIII alone.

experiment was repeated twice with mice that were first injected with 10 μ g mAb14C12, followed 15 minutes later by 1 IU FVIII. No significant difference in FVIII $t_{1/2}$ was observed in the presence of mAb14C12 after either 180 minutes (Table 1) or 360 minutes. Despite extensive homology between mAb14C12 VH and the C2 domain, the former does not seem to interfere with the physiologic activity and clearance of FVIII.

mAb14C12 binds to unmutated CDR and framework residues of mAbBO2C11

Aligning mAb14C12 VH and VL regions with those of mAbBO2C11 identified a total of 40 putative contact residues between the 2 antibodies (data not shown). Five of mAb14C12 residues are homologous to the C2 domain. Interestingly, only 12 of the 40 putative contact residues are located within CDR of mAb14C12. Residues located in the framework regions of mAb14C12, therefore, contribute significantly to the recognition of mAbBO2C11. Again, mutations contribute very little to this interaction, as only 3 of 40 amino acid residues of mAb14C12 are mutated, suggesting that mAb14C12 reacts in its germ line configuration with mAbBO2C11. However, 5 of the 40 putative contact residues within the variable parts of mAbBO2C11 are involved in the binding to C2. The majority (24 of 40) of such residues in mAbBO2C11 is located in framework regions, and only 6 mutations are observed in putative contact residues. This finding suggests that mAb14C12 reacts with the canonical sequence of the subfamily of Abs to which mAbBO2C11 belongs.

Altogether, the neutralization properties of mAb14C12 on mAbBO2C11 binding to, and inhibition of, FVIII, therefore, result from a combination of an extended homology with the C2 domain and recognition of mAbBO2C11 variable part residues not involved in C2 binding. However, attempts to raise anti-C2 inhibitory Abs by subcutaneous (SC) immunization of BALB/c mice with mAb14C12 in CFA/IFA have failed.

mAb14C12 inhibits the binding to C2 of polyclonal antibodies from unrelated patients

The extended complementarity between variable parts of mAb14C12 and those of mAbBO2C11 in germ line configuration suggests that mAb14C12 could neutralize anti-C2 inhibitory antibodies that carry a canonical sequence identical or close to that of mAbBO2C11. This finding is further stressed by the observation that a major proportion of anti-C2 inhibitory antibodies belong to the DP5 subfamily.¹⁴ We, therefore, evaluated the capacity of mAb14C12 to neutralize the inhibitory activity of anti-C2 domain polyclonal antibodies of unrelated patients with hemophilia A. To this end, we used an immunoprecipitation assay in which a radiolabeled C2 domain, obtained by combined transduction-translation with rabbit reticulocytes, was allowed to react in fluid-phase with samples of plasma containing inhibitory Abs to the C2 domain. This assay detects all anti-C2 Abs, irrespective of their capacity to inhibit the function of FVIII.

Figure 3 shows that mAb14C12 neutralized up to 50% of the binding capacity of polyclonal anti-C2 Abs purified from the patient from whom mAbBO2C11 was derived (patient G). In such an assay, mAb14C12 also significantly neutralized polyclonal anti-FVIII Abs obtained from 3 of 6 unrelated patients (patients B, D, E). Idiotypes carried by mAbBO2C11 are, therefore, present on a significant proportion of anti-C2 Abs from unrelated patients. However, the capacity of mAb14C12 to neutralize FVIII inhibition was not paralleled by the results obtained in the immunoprecipita-




Figure 3. mAb14C12 blocks C2 domain recognition by inhibitory Abs in plasma samples taken from patients with hemophilia A inhibitor. Plasma samples of unrelated patients with hemophilia A (A-F), or of the patient from whom mAbBO2C11 was cloned (G), were preincubated with 50, 150, or 450 μ g/ml mAb14C12 before addition of ³⁵S-methionine-labeled C2 domain, to establish how much mAb14C12 was needed to block the binding of C2 to inhibitory antibodies. IgG Abs from plasma were then precipitated by protein-A Sepharose, and residual radioactivity was counted on the pellet. Maximum blocking of C2 binding (100%) was obtained by adding 450 μ g mAb14C12 to the FVIII-mAbBO2C11 mixture. Three of 6 plasma samples (B,D,F) show reactivity with mAb14C12 equivalent to that of the mAbBO2C11 source patient (G). The experiment was run only once and in single determination because of a shortage of plasma material. A control experiment (not shown) was carried out in which human mAbBO2C11 was used instead of polyclonal antibodies, which resulted in 100% neutralization.

tion assay (data not shown), indicating that, even in the presence of anti-C2 Abs, the latter are not necessarily the prominent inhibitors.

Additional experiments were carried out to determine whether the idiootype recognized by mAb14C12 was also presented on mouse anti-FVIII antibodies. A total of 50 mAbs were assayed in a direct binding ELISA, including 3 inhibitory mAbs with C2 specificity; none of such mAbs was, however, competing with mAbBO2C11. mAb14C12 did not recognize any of these mAbs (data not shown).

mAb14C12 neutralizes mAbBO2C11-mediated inhibiting activity in vivo

To determine whether mAb14C12 had the capacity of neutralizing the inhibitory activity of mAbBO2C11 in vivo, FVIII^{-/-} mice were reconstituted with rFVIII and mAbBO2C11.²⁰ The capacity of mAb14C12 to restore the function of FVIII was examined by using various concentrations of mAb14C12. Preliminary experiments have established that the $t_{1/2}$ of mAbBO2C11 and mAb14C12 in FVIII^{-/-} mice were of 3 and 5 days, respectively.

Injection of 1 IU FVIII is sufficient to obtain an average concentration of 0.5 IU/mL. Intravenous administration of 0.5 μ g mAbBO2C11 30 minutes before FVIII completely inhibits FVIII activity (Figure 4). The capacity of mAb14C12 to neutralize mAbBO2C11 in vivo and, therefore, to restore FVIII function was evaluated by mixing 10, 1, and 0.1 μ g mAb14C12 to 0.5 μ g mAbBO2C11 before injection to mice that were injected with 1 IU FVIII 30 minutes later. Figure 4A shows that the mAbBO2C11 inhibitory activity is neutralized in a dose-dependent manner, with 50% neutralization obtained at approximately a one-to-one molar ratio. A maximum of 88.3% (\pm 23.8%) inhibition was observed at a 50-fold molar excess of mAb14C12.

A second series of experiments was carried out in which FVIII^{-/-} mice were first injected with mAbBO2C11 (0.5 μ g) followed 30 minutes later by a mixture of FVIII (1 IU) and various concentrations of mAb14C12. Results similar to the ones reported above with the preincubation of mAb14C12 and mAbBO2C11 were observed with sequential administration of the 2 antibodies (Figure 4B), which indicates that in vivo the affinity of mAb14C12 for mAbBO2C11 is high enough to prevent the binding of mAbBO2C11 to FVIII.




Figure 4. mAb14C12 capacity to restore normal FVIII function in vivo in the presence of mAbB02C11. C57BL/6 FVIII^{-/-} mice injected intravenously with 0.5 µg mAbB02C11 and 1 IU FVIII show complete inhibition of FVIII activity. Injection of complexes made of mAbB02C11 and various concentrations of mAb14C12 (A) or sequential administration of mAbB02C11 followed by mAb14C12 (B) show a dose-dependent neutralization of the inhibitory activity of mAbB02C11 with full FVIII functional activity as measured in a chromogenic assay. Bars show mean of 3 values \pm SD. Under both experimental conditions, \pm 50% restoration was obtained at an mAbB02C11/mAb14C12 equimolar ratio. An unrelated IgG2a mAb had no effect.

Discussion

Selective neutralization of inhibitor Abs represents one of the hoped-for outcomes of immunotherapy strategies. This outcome could in theory be achieved by using FVIII polypeptides containing Ab-binding sites, as proposed early after the cloning of FVIII was obtained.^{5,24} However, Ab epitopes are frequently located in regions of FVIII by which it interacts with physiologic partners such as VWF and/or PL. Hence, fragments of FVIII could interfere with such binding and reduce the procoagulant activity of FVIII. To circumvent this risk, alternative strategies have been sought, notably through the use of synthetic peptides mimicking conformational epitopes with a limited number of contact residues.²⁰ Although promising, this approach suffers from the fact that small peptides have a short $t_{1/2}$ and usually exhibit a low affinity, requiring large doses to achieve a physiologic effect.

A valuable compromise between these 2 possibilities would be to produce large mimotopes, namely FVIII epitopes mimicking natural ones but divergent in amino acid sequence. This would potentially offer better stability and prolonged $t_{1/2}$ as compared with small peptides. Moreover, such large mimotopes can be altered in such a way as to eliminate the risk of interfering with FVIII function, while maintaining a strong, high-affinity reaction with inhibitor Abs. Obtaining large mimotopes by synthesis is cumbersome and impractical. However, anti-idiotypic Abs exhibiting extended homology with the antigen could serve as such, or as a template to prepare large mimotopes.

The production of suitable anti-idiotypic Abs for this purpose has been delayed until specific human mAbs with FVIII inhibitory activity were obtained by derivatization of peripheral memory B cells from patients with hemophilia A with inhibitors.⁷ This, combined to the elucidation of the crystal structure of FVIII domains,⁸ has opened the possibility of exploring at the clonal level the therapeutic potential of anti-idiotypic Abs for FVIII inhibitors.

The results reported here establish the proof of concept that this strategy is appropriate for designing efficient mimotopes for FVIII inhibitors. Starting from a unique human mAb representative of a major class of inhibitors we have produced an anti-idiotypic Ab that combines several properties: (1) it carries an extensive sequence homology with the C2 domain, spanning more than 90 amino acid residues; (2) it shows an affinity for the variable regions of the anti-C2 Ab comparable to that of the inhibitor Ab for C2; (3) it does not interfere with the binding of FVIII to either VWF or PL, nor does it alter the clearance rate of FVIII; and (4) it fully neutralizes the inhibitory activity of mAbB02C11 in a reconstituted FVIII^{-/-} mouse model.

The sequence homology between the variable parts of mAb14C12 and the C2 domain of FVIII is primarily carried by the VH region. Remarkably, the latter contains 31 putative surface-exposed residues identical or similar to C2, including one PL binding site (Leu2251-

Leu2252). Interestingly, the homology includes a significant number of conserved residues of C2, suggesting significant structural homology between the 2 molecules. This homology is illustrated functionally by the observation that neutralization of mAbB02C11 inhibitory activity is obtained at molar equivalence between mAbB02C11 and mAb14C12, both in vitro and in vivo, in keeping with affinity measurement. mAb14C12 can, however, not be considered as carrying a complete internal image of the C2 domain, insofar as it does not bind to VWF or PL, it does not interfere with the binding of FVIII to either VWF or PL and does not elicit anti-C2 Abs by conventional immunization.

An additional reason as to why the homology between the C2 domain and mAb14C12 VH region is interesting is related to the strong participation of residues located in mAb14C12 framework regions (ie, 45%), with only 6 mutated residues over a total of 31 (21%). In other words, the C2 domain presents a sequential and structural homology with some families of Abs in their germ line configuration.²⁶ The C2 domain general organization is made of a barrel of 2 series of 4 beta sheets linked by flexible loops and is reminiscent of the organization of immunoglobulin domains, with loops represented by hypervariable regions, or CDRs, constituting the antigen-binding site.

The results obtained in vivo with FVIII^{-/-} mice reconstituted with human FVIII suggest that mAb14C12 Abs and the like have a therapeutic potential. Full humanization of the Ab would reduce its potential immunogenicity but will also prolong its $t_{1/2}$ up to 3 weeks. A single injection could, therefore, exert a significant effect for more than 1 month, which represents a definite advantage over small peptides. The risk of inducing Abs cross-reacting with the C2 domain on administration of mAb14C12 is likely to be remote, because of the use of such a fully humanized Ab and the fact that administration would be made by the intravenous route only. Besides, only a single or a small number of injections would be all that is required. Finally, the anti-idiotypic Ab variable part can be used as a template for the design of molecules, which would be even more adapted to the neutralization of inhibitors, such as multimeric versions of mAb14C12 VH region,²⁷ or combination of V regions from different anti-idiotypic Abs.

The results presented here show that idiotypes recognized by mAb14C12 are expressed by a significant number of patients that have anti-C2 inhibitory Abs. This seemingly reflects the observation that the interaction between anti-C2 inhibitors similar to mAbB02C11 and mAb14C12 depends on residues present in the Ab germ line sequence. C2 inhibitors are prominent in the production of anti-FVIII inhibitors: mAb14C12 or a derivative of it might, therefore, be helpful for a significant proportion of patients with inhibitor. However, current knowledge suggests that a second C2 epitope is recognized by inhibitory Abs,¹³ which would mean that full neutralization of C2 inhibitors would require another set of anti-idiotypic Abs. We are currently extending our approach to identify such a second epitope.

Currently, 5 main clusters of B-cell epitopes have been described, although the vast majority of antibodies bind to either the

C2 or the A2 domain.²⁸ Efficient use of anti-idiotypic antibodies for patients with inhibitors would, therefore, require in addition to neutralize antibodies toward at least the main A2 domain. Whether anti-A2 antibodies derive from a small number of precursors as do anti-C2 antibodies is not fully understood.²⁹ Obviously, this should be determined through clonal analysis of anti-A2 antibodies derived from patients' memory cell repertoire. Whatever the case, it is likely that efficient neutralization of inhibitors would require a set of anti-idiotypic antibodies or of their derivatives. However, full neutralization might not be an absolute requirement, as a reduction of inhibitor titers to levels of 10 BU/mL or less is sufficient to render patients amenable to tolerance induction using infusions of FVIII.³⁰ Another possible difficulty might emerge from the fact that inhibitor antibodies change specificity over time and could, therefore, "escape" control by anti-idiotypic antibodies. Specificity can change for a number of reasons, associated to the FVIII product used, the conditions under which FVIII is administered (bleeding,

infection), but also as the result of an evolving immune response. The latter can be brought about by somatic hypermutation, receptor editing, or epitope spreading.³¹ The efficacy of anti-idiotypic neutralization of inhibitors will depend on the possibility of generating reagents interacting with inhibitors in germ line configuration, as it is suggested in the present study.

Potential therapeutic applications include the use of anti-idiotypic Abs for short-term neutralization of inhibitors, for instance before a surgical procedure. Such Abs have the potential of interacting with B cells carrying the corresponding idotype. The consequence of this binding can be a functional neutralization of the cell producing the inhibitor or even the translation of a signal leading to target cell apoptosis.³²⁻³⁴ Besides, the heavy chain of the Ab can be engineered in such a way as to favor its interaction with complement or with the Fcγ receptor present on natural killer (NK) cells.³⁵ Therefore, it can be expected that anti-idiotypic Abs would induce a long-lasting elimination of inhibitor production.

References

- Brill E, Rosendaal FR, Krauz W. A meta-analysis based on eight long-term followup studies concerning inhibitors associated with crude or intermediate purity FVIII products. *Thromb Haemostasis*. 1994;72:182-184.
- Ehrenforth S, Krauz W, Sharrer J, et al. Incidence of FVIII and FIX inhibitors in hemophiliacs [letter]. *Lancet*. 1992;339:594.
- Hedner U. Recombinant factor VIIa (Novoseven) as a haemostatic agent. *Semin Hematol*. 2001;38(suppl 12):43-47.
- Martani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. *Semin Thromb Hemost*. 2003;29:89-78.
- Ware J, MacDonald M, Lo M, de Graaf S, Fulcher C. Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide. *Blood Coagul Fibrinolysis*. 1992;3:703-716.
- Hoyer L, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. *Semin Hematol*. 1994;31(2 Suppl 4):1-5.
- Jacquemin M, Desqueper B, Benhida A, et al. Mechanisms and kinetics of FVIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. *Blood*. 1998;92:488-501.
- Epelg P, Jacquemin M, Saint-Remy JM, Stoddard B, Prall K. Structure of FVIII C2 domain-immunoglobulin G4 kappa Fab complex: identification of an inhibitory antibody epitope on the surface of FVIII. *Blood*. 2001;98:13-19.
- Algman M, Dietrich G, Nydegger U, Boelidau D, Sultan Y, Kazatchkine M. Natural antibodies to FVIII (anti-hemophilic factor) in healthy individuals. *Proc Natl Acad Sci U S A*. 1992;89:3785-3789.
- Giles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic. *J Clin Invest*. 1994;94:1498-1505.
- Giles JG, Desqueper B, Lank H, Vermeylen J, Saint-Remy JM. Neutralizing anti-idiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. *J Clin Invest*. 1996;97:1382-1388.
- Pascual V, Capra J. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist. *J Clin Invest*. 1998;101:1367-1368.
- Giles JG, Arnout J, Vermeylen J, Saint-Remy JM. Anti-FVIII antibodies of hemophilic patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. *Blood*. 1993;82:2462-2461.
- van den Brink E, Bril W, Turenhout E, et al. Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. *Blood*. 2002;99:2828-2834.
- Jacquemin M, Benhida A, Pestinck K, et al. Human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. *Blood*. 2000;95:165-163.
- Chellie C, Leek AM, Tramonano A, et al. Conformations of immunoglobulin hypervariable regions. *Nature*. 1989;342:877-883.
- Kabsch W, Sander C. How good are predictions of protein secondary structure? *FEBS Lett*. 1983;156:179-182.
- Myers E, Miller W. Optimal alignment in linear space. *Comput Appl Biosci*. 1988;4:11-17.
- Prall K, Shen B, Takekuma K, Davie E, Fujikawa K, Stoddard B. Structure of the C2 domain of human factor VIII at 1.5 Å resolution. *Nature*. 1999;402:430-442.
- Villard B, Piquet D, Raul G, Leonelli JP, Saint-Remy JM, Grenier C. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. *J Biol Chem*. 2002;277:232-238.
- Singh I, Smith A, Venzelagh B, et al. Anti-thrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine venous thrombosis model. *Blood*. 2002;99:3235-3240.
- d'Oiron R, Laverigne J-M, Lavendhomme R, et al. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. *Blood*. 2004;103:155-167.
- Benko E, Yakhyasov A, Mikhailenko I, Strickland D, Baranov A. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. *J Biol Chem*. 1999;274:27685-27692.
- Lenling P, Nasle J, van den Berg B, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. *J Biol Chem*. 1999;274:23734-23738.
- Hudson P, Bourlart C. Engineered antibodies. *Nat Med*. 2003;9:129-134.
- Fuentes-Prior P, Fujikawa K, Prall K. New insights into the binding interfaces of coagulation factors V and VIII and their homologues: lessons from high resolution crystal structures. *Curr Protein Sci*. 2002;3:313-338.
- Fulcher C, de Graaf Mahoney S, Zimmerman T. FVIII inhibitor IgG subclasses and FVIII polypeptides specifically determined by immunoblotting. *Blood*. 1987;69:1476-1480.
- Scandella DH, Nakai H, Feich M, et al. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. *Thromb Res*. 2001;101:377-385.
- Voorberg J, van den Brink EN. Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII. *Semin Thromb Hemost*. 2000;26:143-150.
- Hay C, Colvin B, Ludlam CA, Hill F, Preston F. Recommendations for the treatment of factor VIII inhibitors: from the UK Hemophilia Centre Directors' Organisation Inhibitor Working Party. *Blood Coagul Fibrinolysis*. 1996;7:134-138.
- McHeyzer-Williams MG. B cells as effectors. *Curr Opin Immunol*. 2003;15:354-361.
- Timmerman J, Debra K, Czerwinski D, et al. Idiotypic-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. *Blood*. 2002;99:1517-1528.
- Vulst W, Levy R, Maloney D. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. *Blood*. 1994;83:899-908.
- Benhamou L, Cazanave P, Sarthou P. Anti-immunoglobulin induce death by apoptosis in WEHI-231 B lymphoma cells. *Eur J Immunol*. 1990;20:1405-1407.
- Bulica A, Moril P, Malos D, Herberman R. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. *Int Rev Immunol*. 2001;20:371-414.

Curriculum vitae Dr. J. Voorberg

Date of birth: 20-11-1961

University training: University of Wageningen, School of Molecular Sciences

Ph.D. training: Department of Molecular Biology under supervision of Prof. dr. H. Pannekoek en Dr. J.A. van Mourik (june 1987-june 1991)

Ph.D. thesis: "Biosynthesis and assembly of human von Willebrand factor" (Nov 1991) University of Amsterdam.

Current position: Senior Scientist at Department of Plasma Proteins, Sanquin Research, Amsterdam

Expertise: Biology of haemostatic proteins with emphasis on factor VIII and von Willebrand factor. Cell biology of von Willebrand factor in endothelial cells constitutes an important line of investigation. During the last five years research on molecular biological aspects of factor VIII inhibitor formation has been studied using phage display and transgenic animal models. These lines of research have resulted in over 50 publications and the following 6 Ph D theses:

"Consequences of haemophilia treatment" Karin Fijnvandraat (1998).

"Small GTP binding proteins involved in regulated secretion of von Willebrand factor from endothelial cells" Hubert P.J.C. de Leeuw (2000).

"Molecular analysis of factor VIII inhibitors using phage display" Edward N. van den Brink (2000).

"Inhibitor formation in mild haemophilia A" Wendy S. Bril (2003).

"Regulation of Weibel-Palade body exocytosis in human endothelial cells" Mariska G. Rondaij (2006).

"Antibodies directed to ADAMTS13 in acquired thrombotic thrombocytopenic purpura" Brenda M. Luken (2006).

Foreign training: Massachusetts Institute of Technology, Boston
Department of Biochemistry (May-Dec, 1986)

University of Minnesota, Minneapolis
Department of Medicine, and Vascular Biology Center, University
of Minnesota Medical School (Feb-July, 2004)

Research grants: Netherlands Organization of Scientific Research (NWO),
Netherlands Heart Foundation (NHS), Netherlands Thrombosis
Foundation (TSN), Landsteiner Foundation for Blood Transfusion
Research (LSBR) and Amsterdam-Leiden-Institute-for-
Immunology (ALIFI).

List of publications

1. Klugkist, J., Voorberg, J., Haaker, H. and Veeger, C. (1987) Characterisation of three different flavodoxins from *Azotobacter vinelandii*. *Eur. J. Biochem.* 155, 33-40.
2. Pannekoek, H. and Voorberg, J. (1989) Molecular cloning, expression and assembly of multimeric von Willebrand factor. *Baillieres Clin. Haematol.* 2, 879-896.
3. Voorberg, J., Fontijn, R., van Mourik, J.A. and Pannekoek, H. (1990) Domains involved in multimer assembly of von Willebrand factor (vWF): multimerization is independent of dimerization. *EMBO J.* 9, 797-803.
4. Van de Ven, W.J., Voorberg, J., Fontijn, R., Pannekoek, H., van den Ouweland, A.M., van Duijnhoven, H.L., Roebroek, A.J. and Siezen, R.J. (1990) Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes. *Mol. Biol. Rep.* 14, 265-270.
5. Leyte, A., Voorberg, J., van Schijndel, H.B., Duim, B., Pannekoek, H. and van Mourik, J.A. (1991) The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor. *Biochem. J.* 274, 257-261.
6. Voorberg, J., Fontijn, R., Calafat, J., Janssen, H., van Mourik, J.A. and Pannekoek, H. (1991) Assembly and routing of von Willebrand Factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. *J. Cell Biol.* 113, 195-205.
7. Ribba, A.S., Voorberg, J., Meyer, D., Pannekoek, H. and Pietu, G. (1992) Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease. *J. Biol Chem.* 267, 23209-23215.
8. Voorberg, J., Fontijn, R., Calafat, J., Janssen, H., van Mourik, J.A. and Pannekoek, H. (1993) Biogenesis of von Willebrand factor-containing organelles in heterologous transfected CV-1 cells. *EMBO J.* 12, 749-758.
9. Voorberg, J., Roelse, J., Koopman, R., Büller, H., Berends, F., ten Cate, J.W., Mertens, K. and van Mourik, J.A. (1994) Association of idiopathic venous thromboembolism with single point-mutation at Arg⁵⁰⁶ of factor V. *The Lancet* 343, 1535-1536.
10. Spaargaren, J., Giesen, P.L.A., Janssen, M.P., Voorberg, J., Willems, G.M. and van Mourik, J.A. (1995) Binding of blood coagulation Factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry. *Biochem. J.* 310, 539-545.

11. Donath, M.-J.S.H., de Laaf, R.T.M., Biessels, P.T.M., Lenting, P.J., van de Loo, J.-W., van Mourik, J.A., Voorberg, J. and Mertens, K. (1995) Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa. *Biochem. J.* 312, 49-55.
12. Roelse, J.C., Koopman, M.M.W., Büller, H.R., ten Cate, J.W., Montaruli, B., van Mourik, J.A. and Voorberg, J. (1996) Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. *Brit. J. Haematol.* 92, 740-743.
13. Voorberg, J., van Stempvoort, G., Klaasse Bos, J.M., Mertens, K., van Mourik, J.A. and Donath, M.-J.S.H. (1996) Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid. *J. Biol. Chem.* 271, 20985-20988.
14. Montaruli, B., Voorberg, J., Tamponi, G., Borchellini, A., Muleo, G., Pannocchia, A., van Mourik, J.A., Schinco, P. (1996) Arterial and venous thrombosis in two Italian families with the factor V Arg⁵⁰⁶ → Gln mutation. *Eur. J. Haematol.* 57, 96-100.
15. Montaruli, B., Borchellini, A., Giorda, L., Bessone, P., van Mourik, J.A., Voorberg, J., Schinco, P. (1996) Factor V Arg⁵⁰⁶ → Gln mutation in patients with antiphospholipid antibodies. *Lupus* 5, 303-306.
16. Voorberg, J., de Laaf, R.T.M., Koster, P.M. and van Mourik, J.A. (1996) Intracellular retention of a factor VIII protein with an Arg²³⁰⁷ → Gln mutation as a cause of haemophilia A. *Biochem. J.* 318, 931-937.
17. Borchellini, A., Fijnvandraat, K., ten Cate, J.W., Pajkrt, D., van Deventer, S.J.H., Pasterkamp, G., Meijer-Huizinga F., Zwart-Huinink, L., Voorberg, J., and van Mourik, J.A. (1997) Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D arginine vasopressin in humans. *Blood* 88, 2951-2958.
18. Fijnvandraat, K., Turenhout, E.A.M., Van den Brink, E., ten Cate, J.W., van Mourik, J.A., Peters, M. and Voorberg, J. (1997) The missense mutation Arg⁵⁹³ → Cys is related to antibody formation in a patient with mild hemophilia A. *Blood* 89, 4371-4377.
19. Fijnvandraat, K., Celie, P.H.N., Turenhout, E.A.M., Cate ten, J.W., van Mourik, J.A., Mertens, K., Peters, M. and Voorberg, J. (1998) A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. *Blood* 91, 2347-2353.
20. de Leeuw, H.P.J.C., Koster, P.M., Calafat, J., Janssen, H., van Zonneveld A.-J., van Mourik, J.A. and Voorberg, J. (1998) Small GTP-binding proteins in human endothelial cells. *Brit. J. of Haematol.* 103, 15-19.

21. Van den Brink, E.N., Timmermans, S.M.H., Turenhout, E.A.M., Bank, C.M.C., Fijnvandraat, K., Voorberg, J. and Peters, M. (1999) Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg⁵⁹³ → Cys substitution. *Thromb. Haemost.* 81, 723-726.
22. De Leeuw, H.P.J.C., Wijers-Koster, P.M., van Mourik J.A. and Voorberg, J. (1999) Small GTP-binding protein RalA associates with Weibel-Palade bodies in endothelial cells. *Thromb. Haemost.* 82, 1177-1181.
23. Van den Berg, H.M., Roosendaal, G., Voorberg, J. and Mauser-Bunschoten, E.P. (1999) Inhibitor development in a multitransfused patient with severe haemophilia A. *Thromb. Haemost.* 82, 151-152 (letter to the editor).
24. Van den Brink, E.N., Turenhout, E.A.M., Davies, J., Bovenschen, N., Fijnvandraat, K., Ouwehand, W.H., Peters, M. and Voorberg, J. (2000) Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. *Blood* 95, 558-563.
25. Roelse J.C., de Laaf R.T.M., Timmermans, S.M.H., Peters, M., van Mourik, J.A. and Voorberg, J. (2000) Intracellular accumulation of factor VIII induced by missense mutations Arg⁵⁹³ → Cys and Asn⁶¹⁸ → Ser explains cross-reacting material-reduced haemophilia A. *Brit. J. Haematol.* 108, 241-246.
26. Van den Brink, E.N., Turenhout, E.A.M., Bank, C.M.C., Fijnvandraat, K., Peters, M. and Voorberg, J. (2000) Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. *Blood* 96, 540-545.
27. Voorberg, J. and Van den Brink, E.N. (2000) Phage display technology; a tool to explore the diversity of inhibitors to blood coagulation factor VIII. *Seminars in Thrombosis and Haemostasis*, 26, 143-150.
28. Van den Brink, E.N., Turenhout, E.A.M., Wijn-Maas, E.C.M., van der Meer, F.J.M., Voorberg, J. and Bosch L.J. (2000) Disappearance of factor VIII autoantibodies preceding autoimmune haemolytic anemia. *Haemophilia*, 6, 698-701.
29. Echard, A., Obdam, F.J., De Leeuw, H.I.P.C., Jollivet, F., Savelkoul, P., Hendriks, W., Voorberg, J., Goud, B. and Franssen, J.A.M. (2000) Alternative splicing of the human Rab6A gene generates two close but functionally different isoforms. *Mol.Biol.Cell*, 11, 3819-3833.
30. Van den Brink, E.N., Turenhout, E.A.M., Bovenschen, N., Heijnen, B.G.A.D.H., Mertens, K., Peters, M. and Voorberg, J. (2001) Multiple VH genes are used to

assemble human antibodies directed towards the A3-C1 domains of factor VIII. *Blood* 97, 966-972.

31. De Leeuw, H.J.P.C., Fernandez-Borja, M., Reits, E.A.J., Wijers-Koster, P.M., Neefjes, J., van Mourik, J.A. and Voorberg, J. (2001) Small GTP binding protein Ral mediates regulated exocytosis of von Willebrand factor by endothelial cells. *Arterioscler Thromb Vasc Biol.* 21, 899-904.
32. Vlot, A.J., Wittebol, S., Strengers, P.F.W., Turenhout, E.A.M., Voorberg, J., van den Berg, M.H. and Mauser-Bunschoten, E.P. (2002) Factor VIII inhibitor in a mild haemophilia A patient with an Asn⁶¹⁸→Ser mutation responsive to a combination of immune tolerance induction and cyclophosphamide. *Brit. J. Haematol.* 117, 136-140.
33. Van Mourik, J.A., Romani de Wit, T., and Voorberg, J. (2002) Biogenesis and exocytosis of Weibel Palade bodies. *Histochemistry and Cell Biology*, 117, 113-122.
34. Bril, W.S., Turenhout, E.A.M., van den Brink, E.N., Kaijen, P.H.P., Peters, M. and Voorberg, J. (2002) Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg³⁹³→Cys mutation using phage display. *Brit. J. of Haemat.*, 119, 393-396.
35. Van den Brink, E.N., Bril, W.S., Turenhout, E.A.M., Zuurveld, M., Bovenschen, N., Peters, M., Yee, T.T., Mertens, K., Lewis, D.A., Ortel, T.L., Lollar, P., Scandella, D., and Voorberg, J. (2002) Two classes of germline genes both derived from the VH1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. *Blood* 99, 2828-2834.
36. Romani de Wit, T., de Leeuw, H.P.J.C., Rondaij M.G., de Laaf R.T.M., Sellink E, Brinkman H-J, Voorberg, J. and van Mourik, J.A. (2003) Von Willebrand factor targets IL-8 to Weibel-Palade bodies. *Exp Cell Research* 268, 67-74.
37. Fijnvandraat K, Bril W.S., and Voorberg, J. (2003) Immunobiology of inhibitor development in haemophilia A. *Seminars in Thrombosis and Haemostasis*, 29, 61-68.
38. Bovenschen N, Boertjes RC, van Stempvoort G, Voorberg, J. Lenting PJ, Meijer AB and Mertens K. (2003) Low-density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. *J. Biol. Chem.* 278, 9370-9377.
39. Romani de Wit, Rondaij MG, Hordijk PL, Voorberg, J. and van Mourik JA. (2003) Real-time imaging of the dynamics and secretory behaviour of Weibel-Palade bodies. *Arterioscler Thromb Vasc Biol.* 23, 755-761.
40. Astermark J, Voorberg, J. Lenk H, DiMichele D, Shapiro A, Tjonnford G and Berntorp E. (2003) Impact of inhibitor epitope profile on the neutralizing effect against

plasma-derived and recombinant factor VIII concentrates in vitro. *Haemophilia*, 9, 567-572.

41. Schatz S, Turecek PL, Fiedler C, Zimmermann K, Gritsch H, Voorberg J, Schwarz HP, Dorner F and Scheiflinger F (2003) Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse model. *Br. J. Haematol.* 123, 692-695.
42. Rondaij MG, Sellink E, Gijzen KA, ten Klooster JP, Hordijk PL, van Mourik JA and Voorberg J. (2004) Small GTP binding protein Ral is involved in cAMP-mediated release of von Willebrand factor from endothelial cells. *Arterioscler Thromb Vasc Biol.* 24, 1315-1320.
43. Bril WS, MacLean PE, Kaijen PH, van den Brink EN, Lardy NM, Fijnvandraat K, Peters M and Voorberg J. (2004) HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation. *Haemophilia* 10, 509-514.
44. Luken BM, Turenhout EAM, Hulstein JJ, van Mourik JA, Fijnheer R and Voorberg J. (2005) The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. *Thromb Haemost* 93, 267-274.
45. Lewis DA, Bovenschen N, Mertens K, Voorberg J and Ortel TL. (2005) Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII. *Thromb Haemost* 93, 833-841.
46. Rondaij MG, Bierings R, Kragt A, Gijzen KA, Sellink E, van Mourik JA, Fernandez-Borja M, Voorberg J (2006) Dynein-dynactin complex mediates protein kinase A-dependent clustering of Weibel-Palade bodies in endothelial cells. *Arterioscler Thromb Vasc Biol* 26, 49-55.
47. Dekker RJ, Boon RA, Rondaij MG, Kragt A, Volger OL, Elderkamp YW, Meijers JC, Voorberg J, Pannekoek H and Horrevoets AJ (2006) KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. *Blood* 107, 4354-4363.
48. Rondaij MG, Bierings R, Kragt A, van Mourik JA and Voorberg J (2006) Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. *Arterioscler Thromb Vasc Biol* 26, 1002-1007.
49. Bril WS, van Helden PW, Hausl C, Zuurveld MG, Ahmad RU, Hollestelle MJ, Reitsma PH, Fijnvandraat K, van Lier RA, Schwarz HP, Mertens K, Reipert BM, Voorberg J (2006) Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg(593) to Cys substitution. *Thromb Haemost* 95, 341-347.

50. Bovenschen N, Van Stempvoort G, Voorberg J, Mertens K, Meijer AB (2006) Proteolytic cleavage of factor VIII heavy chain is required to expose the binding site for low density lipoprotein-related protein within the A2 domain. *J Thromb Haemost* 4, 1487-1493.
51. Luken BM, Kaijen PH, Turenhout EA, Kremer Hovinga JA, van Mourik JA, Fijnheer R, Voorberg J. (2006) Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost* 4, 2355-2364.
52. Luken BM, Turenhout EA, Kaijen PH, Greuter MJ, Pos W, van Mourik JA, Fijnheer R and Voorberg J. (2006) Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. *Thromb Haemost* 96, 295-301.
53. Tjernberg P, Vos HL, Spaargaren-van Riel CC, Luken BM, Voorberg J, Bertina RM, Eikenboom JC (2006) Differential effects of the loss of intrachain-versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease. *Thromb Haemost* 96, 717-724.